FIGHTING AGAINST GLOBAL HIV EPIDEMIC: AVAILABLE OPTIONS TO FOCUS ON

Homa Nath Sharma ‘Raju’; Sagar Baral; Yadav Baral

doi:10.29121/granthaalayah.v7.i7.2019.721

Authors

Homa Nath Sharma ‘Raju’ M.Sc. Graduate, Central Department of Microbiology, TU, Kirtipur, Kathmandu, Nepal, Science Teacher, Gandhi Adarsha Secondary, School, Kandaghari, Kathmandu, Nepal, Prospective (Starting on Sep 4, 2019) Ph.D. Student, University of Wyoming, Laramie, WY, USA
Sagar Baral M.B.B.S. Graduate, Institute of Medicine, TU Teaching Hospital, Maharajgunj, Kathmandu, Nepal Medical Officer, Parbat District Hospital, Kusma, Parbat, Nepal
Yadav Baral Undergraduate Student, University of Texas at Arlington, TX, USA

DOI:

https://doi.org/10.29121/granthaalayah.v7.i7.2019.721

Keywords:

HIV, Public Health, HIV Vaccine

Abstract [English]

HIV continues to be a major global public health issue, having claimed more than 32 million lives so far. While great progress has been made in preventing and treating HIV, there is still much to do. A safe and cost-effective vaccine that prevents HIV infection is considered the best strategy for containing the epidemic. However; historically, the vaccine development for HIV prevention has been extremely difficult. Anti-Retroviral Therapy (ART) has improved the quality of life of Human immunodeficiency virus (HIV) patients worldwide. This reality suggests that continuing on HIV vaccine research, now we should also consider applying other short-term available prevention and treatment strategies to mitigate the effect of the epidemic.

Downloads

Download data is not yet available.

References

World Health Organization (WHO). HIV/AIDS: Key facts. www.who.int/news-room/fact-sheets/detail/hiv-aids/. Accessed 17 July, 2019.

United Nations Programme on HIV and AIDS (UNAIDS). Global HIV and AIDS statistics-2019 fact-sheets, www.unaids.org/en/resources/fact-sheet. Accessed July 7, 2019.

United Nations Programme on HIV and AIDS (UNAIDS). UNAIDS data 2018.www.unaids.org. Accessed July 16, 2018.

Center for Disease Control and Prevention (CDC). HIV/AIDS: Basic Statistics.www.cdc.gov/hiv/HIVbasic/statistics/. Accessed April 12, 2019

Bossou A R, Castrillo S, O’Brien K K, et al. Preventive HIV Vaccine: Progress and Challenges. US Pharm. 2015; 40(10):46-50.

Collins F. Vaccine Research: New Tactics for Tackling HIV. http://directorsb/og.nih.gov/2015/06/30/vaccine-research-newtactics-for-tackling-hiv. Accessed September 10, 2015.

Shin Y. Recent Update in HIV Vaccine Development. Clin Exp Vaccine Res. 2016; 5:6-11. http://dx.doi.org/10.7774/cevr.2016.5.1.6.

Burton DR, Ahmed R, Barouch DH, et al. A Blueprint for HIV Vaccine Discovery. Cell Host Microbe. 2012; 12(4):396–407. DOI:10.1016/j.chom.2012.09.008. DOI: https://doi.org/10.1016/j.chom.2012.09.008

Brett-Major D M, Crowell T A, Michael N L. Prospecting for an HIV Vaccine. Tropical Diseases, Travel Medicine and Vaccines. 2017; 3:6. DOI: 10.1186/s40794-017-0050-4. DOI: https://doi.org/10.1186/s40794-017-0050-4

Esparza J. What Has 30 Years of HIV Vaccine Research Taught Us? Vaccines (Basel). 2013; 1(4):513–526. Published 2013 Oct 30. DOI:10.3390/vaccines1040513 DOI: https://doi.org/10.3390/vaccines1040513

Shin SY. Recent Update in HIV Vaccine Development. Clin Exp Vaccine Res. 2016; 5(1): 6–11. DOI:10.7774/cevr.2016.5.1.6 DOI: https://doi.org/10.7774/cevr.2016.5.1.6

Girard MP, Osmanov SK, Kieny MP. A Review of Vaccine Research and Revelopment: The Human Immunodeficiency Virus (HIV) Vaccine. 2006;24(19):4062–4081. DOI: https://doi.org/10.1016/j.vaccine.2006.02.031

Newman PA, Duan N, Rudy ET, Anton PA. Challenges for HIV Vaccine Dissemination and Clinical Trial Recruitment: If We Build It, Will They Come? AIDS Patient Care STDs. 2004a; 18(12):691–701. DOI: https://doi.org/10.1089/apc.2004.18.691

Paterson DL, Swindells S, Mohr J, et al. Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection. Ann Intern Med. 2000;133:21–30. DOI: https://doi.org/10.7326/0003-4819-133-1-200007040-00004

Garcia F, de Lazzari E, Plana M, et al. Long-term CD4+ T-cell Response to Highly Active Antiretroviral Therapy According to Baseline CD4+ T-cell Count. J Acquir Immune Defic Syndr. Jun 1 2004;36(2):702-713.

Cohen MS. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N Engl J Med 2011; 365(6):493-505. DOI: https://doi.org/10.1056/NEJMoa1105243

Wandeler G, Johnson LF, Egger M. Trends in Life Expectancy of HIV-positive Adults on Antiretroviral Therapy Across the Globe: Comparisons with General Population. Curr Opin HIV AIDS. 2016; 11(5):492–500. DOI:10.1097/COH.0000000000000298. DOI: https://doi.org/10.1097/COH.0000000000000298

Achappa B, Madi D, Bhaskaran U, et al. Adherence to Antiretroviral Therapy Among People Living with HIV. N Am J Med Sci. 2013;5(3):220–223. DOI:10.4103/1947-2714.109196. DOI: https://doi.org/10.4103/1947-2714.109196

Marfatia YS, Jose SK, Baxi RR, Shah RJ. Pre- and Post-sexual Exposure Prophylaxis of HIV: An update. Indian J Sex Transm Dis AIDS. 2017;38(1): 1–9. DOI:10.4103/ijstd.IJSTD_26_17 DOI: https://doi.org/10.4103/ijstd.IJSTD_26_17

US Preventive Service Task Force. Recommendation Statement. Pre-exposure Prophylaxis on HIV Infection. JAMA.2019;321(22):2203-2213. https://www.uspreventiveservicestaskforce.org/Page/Name/recommendations. DOI:10.1001/jama.2019.6390. DOI: https://doi.org/10.1001/jama.2019.6390

Salehi B, Kumar NVA, Şener B, et al. Medicinal Plants Used in the Treatment of Human Immunodeficiency Virus. Int J Mol Sci. 2018;19(5):1459. Published 2018 May 14. DOI 10.3390/ijms19051459 DOI: https://doi.org/10.3390/ijms19051459

De Clereq. Current Lead Natural Products for the Chemotherapy of Human Immunodeficiency Virus Infection. Med Res Rev. 2000;20:323–349. DOI: https://doi.org/10.1002/1098-1128(200009)20:5<323::AID-MED1>3.0.CO;2-A

Kong J M, Goh N K, Chia L S, Chia T F. Recent Advances in Traditional Plant Drugs and Orchids. Acta Pharmacol Sin. 2003;24:7–21.

Prodger J L, Kaul R. The Biology of How Circumcision Reduces HIV Susceptibility: Broader Implications for the Prevention Field. AIDS Res Ther. 2017;14:49. DOI: 10.1186/s12981-017-0167-6. DOI: https://doi.org/10.1186/s12981-017-0167-6

Ramesh Verma, Pardeep Khanna, Suraj Chawla & Mukesh Dhankar (2016) HIV vaccine: Can it be developed in the 21st century? Human Vaccines & Immunotherapeutics. 2016; 12(1): 222-224. DOI: 10.1080/21645515.2015.1064571. DOI: https://doi.org/10.1080/21645515.2015.1064571

National Institute of Allergy and Infectious Diseases (NIAID). Progress toward an HIV Vaccine. www.niaid.nih.gov. Accessed July 7, 2019

Trovato M, D’Apice L, Prisco A, et al. HIV vaccine: A Roadmap among Advancements and Concerns. Int J Mol Scssi. 2018; 19: 1241. DOI: 10.3390/ijms19041241. DOI: https://doi.org/10.3390/ijms19041241